Evidence map›Paper›PMID 32051695›Full record

ReviewDisease markers2020

New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis.

Sara Pagani, Mattia Bellan, Daniele Mauro, Luigi Mario Castello, Gian Carlo Avanzi, Myles J Lewis, Pier Paolo Sainaghi, Costantino Pitzalis, Alessandra Nerviani

Open access · hybridAbstract readReview
In one paragraph

Review in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Elevated Plasma Levels of Growth Arrest Specific 6 (Gas6) Protein in Severe Obesity: Implications for Adipose Tissue and Inflammation.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Mertk: An emerging target in cancer biology and immuno-oncology.International review of cell and molecular biology · 2022
    Article
  15. Review
  16. Review
  17. CD14Arthritis research & therapy · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sara PaganiCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Mattia BellanDepartment of Translational Medicine, Università del Piemonte Orientale (UPO), Novara, Italy.ORCID https://orcid.org/0000-0003-1488-8736
Daniele MauroCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Luigi Mario CastelloDepartment of Translational Medicine, Università del Piemonte Orientale (UPO), Novara, Italy.ORCID https://orcid.org/0000-0001-8248-1976
Gian Carlo AvanziDepartment of Translational Medicine, Università del Piemonte Orientale (UPO), Novara, Italy.
Myles J LewisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0001-9365-5345
Pier Paolo SainaghiDepartment of Translational Medicine, Università del Piemonte Orientale (UPO), Novara, Italy.ORCID https://orcid.org/0000-0001-8322-9158
Costantino PitzalisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Alessandra NervianiCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0003-4064-4014
Queen Mary University of London · GBUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Versus Arthritis 21890
6 · The paper itself

Abstract

Rheumatoid Arthritis (RA) is the most common chronic inflammatory autoimmune disease involving joints. Among several pathogenic mechanisms, the impairment of homeostatic regulators of inflammation seems to be critically important to sustain persistent infiltration and activation of immune and stromal cells within the diseased synovium. Tyrosine kinase receptors Tyro3, Axl, and Mer are members of the TAM family. Upon binding their ligands Growth Arrest-Specific gene 6 (Gas6) and Protein S (ProS1), TAM receptors (TAMs) exert numerous and diverse biologic functions. Activated Axl and Mer, for instance, can negatively regulate the inflammatory cascade and mediate phagocytosis of apoptotic cells, contributing to prevent the development of autoimmunity. Thus, a role for TAMs has been hypothesized in RA. In this review, we will summarise unmet clinical needs in RA, depict the biology of TAMs and TAM ligands, focussing on their ability to regulate the immune system and inflammation cascade, and finally offer an overview of the state-of-the-art literature about the putative role of TAM axis in RA.

Indexed as

Adaptive ImmunityArthritis, RheumatoidAxl Receptor Tyrosine KinaseBiomarkersc-Mer Tyrosine KinaseEpigenesis, GeneticGene Expression RegulationHumansImmunity, InnateLigandsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXL protein, humanAxl Receptor Tyrosine KinaseBiomarkersc-Mer Tyrosine KinaseLigandsMERTK protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesTYRO3 protein, human

Identifiers

PMID32051695
PMCPMC6995487
OpenAlexW3002351161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.